Pharmacy Updates Summary
|
|
|
- Lenard Snow
- 5 years ago
- Views:
Transcription
1 All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 10/28/2014 Effective date: 11/15/2014 Therapeutic Classes reviewed: Pulmonary arterial hypertension (PAH) Topical corticosteroids Topical calcineurin inhibitors Clostridium difficile agents Anti-malarial agents Prior Authorization Criteria Updates Pulmonary arterial hypertension (PAH) Topical corticosteroids Topical calcineurin inhibitors Anti-malarial agents Clostridium dificile agents Policies/Forms Approved None
2 Approved Changes: Pulmonary Arterial Hypertension (PAH) Drug Class Sildenafil Citrate (Revatio ) Sildenafil Citrate (Revatio ) Tadalafil (Adcirca ) 20mg tab PA Required PA Required Excluded 10mg/mL sol Non-formulary Non-formulary Excluded 20mg tab Non-formulary Non-formulary Excluded Ambrisentan (Letairis ) Bosentan (Tracleer ) 5mg tab 10mg tab 62.5mg tab 125mg tab PA Required PA Required Excluded Non-formulary Non-formulary Excluded Macitentan (Opsumit ) Riociguat (Adempas ) 10mg tab Non-formulary Non-formulary Excluded 0.5mg tab 1mg tab 1.5mg tab Prior Authorization Prior Authorization Excluded
3 Treprostinil Inhalation Solution (Tyvaso ) Treprostinil Inhalation Starter Kit (Tyvaso ) Iloprost (Ventavis ) Inhlation Solution 1.74mg/2.9mL 1.74mg/2.9mL 10mcg/mL 20mcg/mL Prior Authorization Prior Authorization Prior Authorization Prior Authorization Excluded Excluded Non-formulary Non-formulary Excluded Topical Corticosteroids Drug Class Ultra High Potency (Group 1): Clobetasol propionate 0.05% cream, emollient Fluocinonide 0.1% cream (Vanos ) Betamethasone dipropionate, augmented 0.05% Non-formulary Non-formulary Non-formulary Non-formulary
4 ointment Betamethasone dipropionate, augmented 0.05% lotion Betamethasone dipropionate, augmented 0.05% gel Clobetasol propionate 0.05% cream Clobetasol propionate 0.05% gel Clobetasol propionate 0.05% ointment Clobetasol 0.05% scalp solution Halobetasol propionate 0.05% ointment High Potency (Group 2):
5 Betamethasone dipropionate, augmented 0.05% cream (Diprolen AF) Desoximetasone 0.25% cream (Topicort ) #120 per 30 #120 per 30 High Potency (Group 3): Betamethasone valerate 0.1% ointment (Valisone) Fluocinonide E (emollient) 0.05% cream (Lidex) Mometasone furoate 0.1% ointment (Elocon) Betamethasone dipropionate 0.05% cream (Diprosone) Fluocinonide 0.05% cream (Dermacin)
6 Medium Potency (Group 4): Fluocinolone acetonide 0.025% ointment (Synalar) Mometasone furoate 0.1% cream (Elocon) Lower to Mid Potency (Group 5): Fluticasone propionate 0.05% cream (Cutivate) Hydrocortisone butyrate 0.1% ointment (Locoid) Desonide 0.1% ointment (DesOwen) Non-formulary Non-formulary Low Potency (Group 6):
7 Desonide 0.05% cream, lotion (Desonate ) Fluocinolone acetonide 0.01% cream (Synalar) Fluocinolone acetonide 0.01% solution (Synalar) Fluocinolone acetonide 0.01% Oil (scalp) (Derma- Smoothe/FS) Fluocinolone acetonide 0.01% Oil (body) (Derma- Smoothe/FS) Least Potent (Group 7): Hydrocortisone (base) 2.5% lotion (Hytone) #240 per 30 with selfgrandfathering #240 per 30 with selfgrandfathering No chnages
8 Hydrocortisone (base) 1.0% lotion (Aquinil HC, Sarnol HC, Cortizone-10) Hydrocortisone (base) 1% cream with aloe #240 per 30 with selfgrandfathering #240 per 30 with selfgrandfathering #240 per 30 with selfgrandfathering Excluded #240 per 30 with selfgrandfathering Topical Steroids Drug Class Tacrolimus (Protopic) 0.03%, 0.1% ointment Pimecrolimus (Elidel) 1% cream, ST with 2 medium to high potency corticosteroids, 2 y/o, QL 30 per 30, ST with 2 medium to high potency corticosteroids, 2 y/o, QL 30 per 30, ST with 2 medium to high potency corticosteroids, 2 y/o, QL 30 per 30, ST with 2 medium to high potency corticosteroids, 2 y/o, QL 30 per 30
9 Antimalarial Drug Class Quinidine Gluconate 324 mg tablets Daraprim (Pyrimethamine) 25 mg Qualaquin (Quinine Sulfate) 324 mg Non formulary Non formulary Non formulary Non formulary Non formulary Non formulary Clostridium Difficile Drug Class Vancomycin capsules (Vancocin ) Fidaxomicin (Dificid ), ST with metronidazole QL #40 per 10, 2 fills per year, ST with metronidazole QL #40 per 10, 2 fills per year Prior Authorization Prior Authorization
10 Proposed Changes Additions Docosanol (Abreva) #2 gm per 30 #2 gm per 30 #2 gm per 30 Nifedipine 10 mg IR Drysol QL #4 per day QL #35 per 30 QL #4 per day QL #35 per 30 Sotalol 80, 120 mg tablet 80 mg: #120 per 30, min 21 y/o 80 mg: #120 per 30, min 21 y/o Ipratropium nasal spray 0.06% (42 mcg), 120 mg: #60 per 30, min 21 y/o #15 per mg: #60 per 30, min 21 y/o #15 per 30 Ipratropium nasal spray #30 per % (21 mcg) Levetiracetam ER 500, #30 per mg tablet Urea 20% cream #85 per 30 Benzoyl peroxide 2% gel Benzoyl peroxide 10% gel #30 per 30 #30 per 30 Excluded (OTC) #85 per 30 Excluded (OTC) Excluded (OTC)
11 Nasalcrom / Cromolyn Nasal Spray Salonpas (methyl salicylate/menth/camph) Albenza 200mg Min Age 2yo Min Age > 18yo, QL #40 per 30 QL#4/fill and max 2 fills/yr Excluded (OTC) Min Age 2yo Excluded, Min Age >18 yo, QL #40 per 30 QL#4/fill and max 2 fills/yr Gender Edit Added Bicalutamide 50mg (Casodex) Gender limit: Male Gender limit: Male Age Edits Removed Phenytoin 50 mg chewable tablets (Dilantin) QL# 180 per 30 QL# 180 per 30
12 Quantity Limits Added Tretinoin all strengths and formulations (topical) < 30 y/o QL of 15 gm for gel 0.01%, 0.025% QL of 20 gm for cream 0.025%, 0.05%, 0.1%; gel 0.1% < 30 y/o QL of 15 gm for gel 0.01%, 0.025% QL of 20 gm for cream 0.025%, 0.05%, 0.1%; gel 0.1% Step Therapy Removed Carisoprodol 350 mg (Soma) QL #120 per 30 QL #120 per 30 Quantity Limits Increased Triamcinolone Acetonide 0.1 % Cream #454 per 30 #454 per 30
13 Terazosin 5mg with QL#3/day with QL#3/day Mycophenolate 250mg with QL#6/day with QL#6/day Deletion ALTRETAMINE (HEXALEN) Non formulary Non formulary Aquaphor No Changes Excluded No Changes Atropine Sulfate; Non-formulary Non-formulary Hyoscyamine Sulfate; Phenobarbital; Scopolamine Hydrobromide (Donnatal ) elixir CAFFEINE; ERGOTAMINE Non formulary Non formulary TARTRATE (Cafergot tablets) CAFFEINE; ERGOTAMINE Non formulary Non formulary TARTRATE (Migergot suppositories) CHLORAMBUCIL (LEUKERAN) Non formulary Non formulary Dicyclomine Non-formulary Non-formulary
14 Hydrochloride10mg/5ml solution ERGOTAMINE TARTRATE Non-formulary Non-formulary 2MG SUBL (ERGOMAR) ESTRAMUSTINE PHOSPHATE SODIUM (EMCYT) Non formulary Non formulary ETOPOSIDE Non formulary Non formulary Hyoscyamine Non-formulary Non-formulary 0.125mg/5ml elixir Hyoscyamine Sulfate Non-formulary Non-formulary 0.125mg/5ml solution Intuniv ER (Guanfacine Non Non Excluded ER) 1mg, 2mg, 3 mg, 4 mg Isopropyl Alcohol 7% No Changes Excluded No Changes (alcohol preps) OXYCODONE (OXECTA) Non-formulary Non-formulary Piperonyl butoxide ; No Changes Excluded No Changes Pyrethrins 4%/0.33% (Lice Treatment Rinse) Piperonyl Excluded No Changes Butoxide;Pyrethrins 4%/0.33% (Lice Killing Shampoo) PROCARBAZINE Non formulary Non formulary HYDROCHLORIDE (MATULANE) Psyllium 520mg (Konsyl) No Changes Excluded No Changes TEMOZOLOMIDE 5, 20, Non formulary Non formulary
15 100, 250 THIOGUANINE (TABLOID) Non formulary Non formulary Trazodone 300 mg Non formulary Non formulary ALBUTEROL SULFATE; Non-formulary Non-formulary IPRATROPIUM BROMIDE 103MCG/ACT; 18MCG/ACT (COMBIVENT) Eflornithine 13.9% Excluded Excluded Excluded CREAM (VANIQA) Finasteride 1 mg Excluded Excluded (Propecia) ALISKIREN FUMARATE Non-formulary Non-formulary (TEKTURNA) ALISKIREN FUMARATE; Non-formulary Non-formulary AMLODIPINE BESYLATE (TEKAMLO) ALISKIREN FUMARATE; Non-formulary Non-formulary AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE (AMTURNIDE) ALISKIREN FUMARATE; Non-formulary Non-formulary HYDROCHLOROTHIAZIDE (TEKTURNA HCT) AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL Non-formulary Non-formulary
16 (TRIBENZOR) AMLODIPINE BESYLATE; Non-formulary Non-formulary HYDROCHLOROTHIAZIDE; VALSARTAN (EXFORGE HCT) AZILSARTAN (EDARBI) Non-formulary Non-formulary DESVENLAFAXINE Non-formulary Non-formulary SUCCINATE MONOHYDRATE (PRISTIQ) DICLOFENAC (ZIPSOR) Non-formulary Non-formulary DICLOFENAC POTASSIUM Non-formulary Non-formulary 50 mg POWDER PACK (CAMBIA) Doxycycline hyclate Non-formulary Non-formulary 20mg kit (Alodox convenience kit) EPROSARTAN MESYLATE; Non-formulary Non-formulary HYDROCHLOROTHIAZIDE (TEVETEN HCT) FENOPROFEN (NALFON) Non-formulary Non-formulary FENTANYL CITRATE Non-formulary Non-formulary SOLUTION (LAZANDA) FLUVASTATIN ER 80 MG Non-formulary Non-formulary (LESCOL XL) HYDROCHLOROTHIAZIDE; Non-formulary Non-formulary OLMESARTAN MEDOXOMIL (BENICAR HCT) HYDROXYPROGESTERON E CAPROATE (MAKENA) Excluded Excluded
17 LOVASTATIN ER Non-formulary Non-formulary (ALTOPREV) LOVASTATIN; NIACIN Non-formulary Non-formulary (ADVICOR) METFORMIN ; Non-formulary Non-formulary PIOGLITAZONE METFORMIN ER Non-formulary Non-formulary (GLUMETZA) METFORMIN; Non-formulary Non-formulary ROSIGLITAZONE (AVANDAMET) NAPROXEN 24 HR Non-formulary Non-formulary (NAPRELAN) NEBIVOLOL Non-formulary Non-formulary HYDROCHLORIDE (BYSTOLIC) NIACIN; SIMVASTATIN Non-formulary Non-formulary (SIMCOR) OLMESARTAN (BENICAR) Non-formulary Non-formulary OLOPATADINE Non-formulary Non-formulary HYDROCHLORIDE (PATANASE) PAROXETINE MESYLATE Non-formulary Non-formulary (PEXEVA) Peginterferon Alfa-2b Non-formulary Non-formulary (Peg-Intron) PITAVASTATIN (LIVALO) Non-formulary Non-formulary ROSIGLITAZONE Non-formulary Non-formulary (AVANDIA) TOCILIZUMAB (ACTEMRA) SC Non-formulary Non-formulary
18 VILAZODONE Non-formulary Non-formulary HYDROCHLORIDE (VIIBRYD) ZAFIRLUKAST Non-formulary Non-formulary (ACCOLATE) Atropine Sulfate; Non-formulary Non-formulary Excluded Hyoscyamine Sulfate; Phenobarbital; Scopolamine Hydrobromide (Donnatal ) tablets Hyoscyamine CR Non-formulary Non-formulary mg tabs (Symax Duotab) Mesalamine enema kit (Rowasa) Non-formulary Non-formulary *changes effective 11/15/14 CWRAP = Medicare/Medi-Cal
Comparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria
ALBENDAZOLE Mercy Care ALBENZA TABLET 200 MG ORAL Refer to PA Guideline for approval criteria 1 BRIMONIDINE-TIMOLOL COMBIGAN SOLUTION 0.2-0.5 % OPHTHALMIC Requires use of separate ingredients for at least
Pharmacy Benefit Determination Policy
Policy Subject: Atopic Dermatitis Agents Policy Number: SHS PBD18 Category: Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS PPO ASO s:
The Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria
Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
TRICARE Uniform Formulary. Pre-Authorization Requirements
TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because
Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir
Acyclovir Ointment Mercy Care Plan acyclovir ointment 5 % external Requires use of oral Acyclovir 1 Adcirca ADCIRCA TABLET 20 MG ORAL Requires use of Sildenafil 2 Albenza ALBENZA TABLET 200 MG ORAL Requires
Quarterly pharmacy formulary change notice
Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics
Eucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
High-Cost Drug Exclusions
PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
Eucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
ALLERGIC RHINITIS-NASAL
ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step
Comparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
Aetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
High-Cost Drug Exclusions
Pharmacy Services High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at
Step Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
2015 Medicare Step Therapy Criteria. Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014
2015 Medicare Step Therapy Criteria Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014 1 Table of Contents AMITIZA, LINZESS... 3 ANTIDEPRESSANTS - Viibryd / Pexeva / Pristiq / Desvenlafaxine...
TennCare Program TN MAC Price Change List As of: 03/30/2017
1 TN List Run : 03/30/17 Old PRAZOSIN HCL 5 MG CAPSULE ORAL 03/29/2017 1.11209 1.12560 ( 1.2) CAPTOPRIL 12.5 MG TABLET ORAL 07/07/2015 1.07191 1.10416 ( 2.9) ISOSORBIDE DINITRATE 5 MG TABLET ORAL 03/29/2017
Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan
Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review
HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other SELEXIPAG UPTRAVI 42922 TREPROSTINIL ORENITRAM ER 40827 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request
Drug Formulary Update, April 2017 Commercial and State Programs
Drug Formulary Update, April 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
Step Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet
2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY
South Country Health Alliance 2017 Step Therapy Formulary ID: 17431 Last Updated: 10/20/2017 Effective Date: 11-01-2017 ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY BENICAR 20 MG BENICAR 40 MG BENICAR 5
The safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
Step Therapy Criteria 2019
Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD
CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
Network Health Insurance Corporation Upcoming Negative Changes to the Medicare Part D Formulary
Requesting an Exception to the Formulary You can ask Network Health Insurance Corporation to make an exception to our coverage rules. Generally, we will only approve your request for an exception if alternative
2017 Formulary Changes Year to Date
2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or
Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
2014 Medicare Step Therapy Criteria. Last Modified: Last Submitted to CMS:
2014 Medicare Step Therapy Criteria Last Modified: 09.30.2014 Last Submitted to CMS: 09.02.2014 1 Table of Contents AMITIZA, LINZESS... 3 ANTIDEPRESSANTS - Viibryd / Pexeva / Pristiq / Desvenlafaxine...
Pharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
WVCH Formulary Additions Effective 01/01/2016 Name Strength Dosage Form Route Formulary Restrictions
WVCH Formulary Additions Effective 01/01/2016 Name Strength Dosage Form Route Formulary Restrictions ANORO ELLIPTA 62.5-25MCG BLST W/DEV INHALATION ARCAPTA NEOHALER 75 MCG CAP W/DEV INHALATION CALCIPOTRIENE
Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)
![Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)](/thumbs/85/91743011.jpg "Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)")
CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018
LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION
LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION Added Prior Authorization 7/1/17 CORLANOR 5 MG TABLET Added Prior Authorization 7/1/17 CORLANOR 7.5 MG TABLET Added Prior Authorization 7/1/17
Effective for all members on August 1, 2017
August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List
ADDITIONAL DRUG LISTING FOR MEDICARE & MEDI-CAL MEMBERS
MEDICARE & MEDICAL MEMBERS! Please read carefully! The following pages include additional drugs which may be covered for you with your doctor s prescription by MediCal (Medicaid). These drugs CANNOT be
Quarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Provider update Summary: The formulary changes listed in the table below were reviewed and approved at our second quarter 2018, Pharmacy and Therapeutics Committee
Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)
Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so
Step Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
84:00. Skin and Mucous Membrane Agents. 84:00 Skin and Mucous Membrane Agents
Skin and Mucous Membrane Agents Skin and Mucous Membrane Agents COMPOUND PRESCRIPTION 00000999119 00000999112 COMPOUND - RETINOIC ACID (TRETINOIN) () MISCELLANEOUS COMPOUND To be used when the compound
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Technology Appraisals and Guidance Information Services Static List Review (SLR) report Title and TA publication number of static topic: Final decision:
2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
Pharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 01/21/2015 Effective date: 02/21/2015 Therapeutic Classes reviewed: Allergen-Specific Immunotherapy
Drug Class Monograph. Policy/Criteria:
Drug Class Monograph Class: Pulmonary Arterial Hypertension Agents Drugs: Adcirca (tadalafil), Adempas (riociguat), Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil),
2017 Step Therapy Criteria
FRESENIUS TOTAL HEALTH 2017 Step Therapy Updated 07/01/2017. For more recent information or other questions, please contact Fresenius Total Health Customer Service at 1-855-598-6774 / TTY 1-844-209-9094.
Pharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 04/15/2015 Effective date: 05/15/2015 Therapeutic Classes reviewed: Testosterone replacement
$4 Prescription Program May 5, 2008
Allergies & Cold and Flu Benzonatate 100mg 14 42 Ceron DM syrup 120ml 360ml Ceron drops* 30ml 90ml Dec-Chlorphen drops* 30ml 90ml Dec-Chlorphen DM syrup* 118ml 354ml Loratadine 10mg 30 90 Promethazine
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.PHAR.336 Effective Date: 05.01.17 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
WellCare of South Carolina Preferred Drug List Update
WellCare of South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on August 21,
TN Cover Rx Tennessee CoverRx MAC Price Change List As of: 04/26/2018
1 Tennessee CoverRx List Run : 04/26/18 Dosage Form amiodarone HCl 200 MG TABLET ORAL 04/25/2018 0.16102 0.14405 11.8 hydralazine HCl 100 MG TABLET ORAL 04/25/2015 0.11390 0.10854 4.9 hydralazine HCl 25
OTC PRODUCTS. 4 Gama Benzene HCL 0.1% + Proflavine Hermisulphate 0.1% + Cetrimide 0.45% Cream
OTC PRODUCTS SR. No. COMPOSITION Allantoin 0.2% + Dimethicone 1% + Urea 10% + Propylene Glycol 5% + Glyserine 5% + 1 Light Liquid Paraffin 8% Cream (FOOT CREAM) 2 Aquous Cream 3 Cetrimide 0.5% + Chlorhexidine
2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)
207 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Plus Plan (HMO) H5087-002, H5087-07 This is a listing of the changes that have occurred in our formulary.
Pharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines
Drug Class Literature Scan: Topical Steroids
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Children s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2020-10 Program Prior Authorization/Medical Necessity PAH Agents Medication Adcirca (tadalafil), Adempas (riociguat), Letairis
2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)
2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Best Plan (HMO) H5087-005 This is a listing of the changes that have occurred in our formulary. Please
Product List Finished Dosage Forms (FDF) B2B Business
Product List 2017 Finished Dosage Forms (FDF) B2B Business Anaesthetics Dermatology Lidocaine Lidocaine and Prilocaine Dexmedetomidine Hydrochloride Anti-Infectives Amoxicillin Trihydrate and Potassium
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Step Therapy Reference Number: HIM.PA.109 Effective Date: 08.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end
1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
WellCare s South Carolina Preferred Drug List Update
WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/03/2015.
ANTIDEPRESSANTS - BUPROPION
Step Therapy Paramount Medicare Formulary 2012 Formulary ID 12112, Version 22. CMS Approved 10-23-2012. ANTIDEPRESSANTS - BUPROPION Aplenzin may be given. Step 1 Drug(s): Budeprion Sr, Budeprion Xl, Bupropion
BlueLink TPA FlexRx Updates
BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%
Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates
Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates April 2018 TRADE NAME (generic name) or generic name Brand/Generic Description of Change abacavir sulfate soln 20 mg/ml (base equiv) Generic
$4 Prescription Program October 23, 2007
Allergies & Cold and Flu Benzonatate 100mg 14 Ceron DM syrup Ceron drops Dec-Chlorphen drops Dec-Chlorphen DM syrup 118ml* Loratadine 10mg Promethazine DM syrup Trivent DPC syrup * Antibiotic Treatments
PULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
WellCare s South Carolina Preferred Drug List Update
WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/21/2017.
Health Partners Medicare Prime 2019 Formulary Changes
Health Partners Medicare Prime 2019 Formulary Changes Changes occur, for example, because new drugs come on the market, a drug is moved to a different cost-sharing level (tier), or a generic version becomes
BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
AETNA BETTER HEALTH January 2017 Formulary Change(s)
AETNA BETTER HEALTH January 2017 Formulary Change(s) The following updates will be made to the Aetna Better Health of MI formulary on March 1, 2017 Drug Name, Strength, Dosage Form ALFUZOSIN HCL ER 10
San Francisco Health Plan (SFHP)
San Francisco Health Plan (SFHP) The following changes to SFHP formulary and prior authorization criteria were reviewed and approved by the SFHP Pharmacy and Therapeutics (P&T) Committee on 04/18/2018.
ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS
SR. NO 1 ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS Paracetamol 500 mg, Phenylephrine HCL 5 mg With Chlorpheniramine Maleate 2 mg & Caffeine 30 mg Tablets 2 Salbutamol Tablets BP 2 mg 3 Salbutamol Tablets
WellCare Signature (PDP) and WellCare Classic (PDP) Formulary Addendum
WellCare Signature (PDP) and WellCare Classic (PDP) Formulary Addendum This is a listing of the changes that have occurred in our formulary. Please carefully review these changes and call WellCare if you
ICP Formulary Updates
ICP Formulary Updates July 2017 TRADE NAME (generic name) adapalene cream 0.1% 2017-07-01 Removal adapalene gel 0.3% 2017-07-01 Removal adefovir dipivoxil tab 10 mg 2017-07-01 Removal ADVAIR DISKUS (fluticasone-salmeterol
NHA Automatic Therapeutic Interchange Policy (Updated July 23, 2015)*
NHA Automatic Therapeutic Interchange Policy (Updated July 23, 2015)* The following interchanges have been implemented to ensure rational use of select drugs, to decrease drug expenditures, and to allow
2014 Quantity Limits (QL) Criteria
2014 Quantity Limits (QL) Criteria Certain drugs covered through your EmblemHealth Medicare HMO/PPO Medicare Plan are covered for only a limited quantity. We do this to ensure compliance with the US Food
Allergy, Cough and Cold. Analgesic. Anti-Anxiety. Antibiotic
For your convenience, this list is sorted by drug category. Drugs are categorized based on their most common use and may be included in more than one category. Drugs are not categorized by all of their
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Enstilar, Sernivo, Taclonex) Reference Number: CP.CPA.255 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Step Therapy Reference Number: HIM.PA.109 Effective Date: 08.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end
Riesbeck's Pharmacy Reward Club Generic Medication List September 2017
Drug Category Allergy, Cold & Flu Antibiotic Treatments Arthritis & Pain Riesbeck's Benzonatate 100mg cap 14 42 Diphenhydramine HCl Cap 50 MG 30 90 Diphenhydramine HCl Liquid 12.5 MG/5ML 720ml 2160ml Hydroxyzine
ANTICONVULSANTS. Details
ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET APTIOM 800 MG TABLET BANZEL 200 MG TABLET BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG TABLET FYCOMPA 0.5 MG/ML ORAL SUSPENSION
Generics. Lead with. Prescription Step Therapy Program
Lead with Generics Prescription Step Therapy Program WWW.BCBSLA.COM 04HQ3972 R11/10 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity Company GENERIC DRUGS: A
Neighborhood Medicaid Formulary Changes: June 2017
Neighborhood Medicaid Formulary Changes: June 2017 The following changes to the Neighborhood Medicaid Formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. All changes were
ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria
ANTIDEPRESSANTS Trintellix 10 mg tablet Trintellix 20 mg tablet Trintellix 5 mg tablet Viibryd 10 mg (7)-20 mg (23) tablets in a dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet
Alprazolam 0.25mg, 0.5mg, 1mg tablets
Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service
Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E
Santa Clara Family Health Plan Cal MediConnect Formulary List of Step Therapy Requirements Effective: 12/01/2018 13027.12E ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET
PRESCRIPTION SAVINGS CLUB FLAT- PRICED GENERIC DRUG LIST (EMDEON) Effective August 20, 2014
PRESCRIPTION SAVINGS CLUB FLAT- PRICED GENERIC DRUG LIST (EMDEON) Effective August 20, 2014 The Prescription Savings Club provides its members with significant savings on prescription medications. The
ANTICONVULSANTS. Details
ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension
AETNA BETTER HEALTH January 2017 Formulary Change(s)
AETNA BETTER HEALTH January 2017 Formulary Change(s) The following updates will be made to the Aetna Better Health of MI formulary on February 1, 2017 Drug Name, Strength, Dosage Form IVERMECTIN 3 MG TABLET
High-Cost Drug Exclusions
PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at